Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Astrocyte-mediated neuropil resistance (also known as parenchymal resistance or RP) is a physiological parameter that describes the hydraulic resistance to fluid flow within the brain's interstitial space [1, 10]. This resistance is primarily regulated by astrocytes, which control the volume and tortuosity of the extracellular space (ECS) through their perivascular endfeet and the expression of proteins such as Aquaporin-4 (AQP4) [2, 21]. In neurodegenerative diseases like Alzheimer's, increased neuropil resistance is associated with impaired glymphatic clearance of toxic proteins, including amyloid-beta and tau [12, 18]. Therapeutic candidates like ACX-02 and ACX-14 are designed to reduce this resistance, thereby facilitating the brain's natural waste-clearance mechanisms [1, 22]. By enhancing glymphatic flux, these interventions aim to reduce the accumulation of protein aggregates and slow the progression of cognitive decline [10, 23].
Reduction of parenchymal resistance to facilitate glymphatic flow and enhance the clearance of neurotoxic proteins such as amyloid-beta and tau.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Astrocyte-mediated neuropil resistance (RP).